The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM). Investigators have identified a biomarker associated with poor outcomes in multiple myeloma (MM) that ...

Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer. Each 5% increase in TILs was ...

A subset of breast cancers amplifies the ERBB2 gene at chromosomal region 17q12 and overexpresses its protein product, the ERBB2 tyrosine kinase receptor (also called HER2). This alteration is ...

Higher TIL levels in ERBB2-positive breast cancer correlate with improved DDFS and OS, suggesting a prognostic role. Patients with TILs greater than or equal to 20% may safely undergo shorter ...

A recent analysis suggested that, while ERBB2-low advanced gastric cancer was associated with significantly shorter progression-free survival (PFS) and overall survival than ERBB2-null disease in ...

The inaccuracy of standard immunohistochemistry testing to identify ERBB2-low breast cancer could lead to real-world mismanagement of patients who may be eligible for fam-trastuzumab deruxtecan-nxki.

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers. Data showed that the objective ...

Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a ...

Data from the Phase Ib Beamion LUNG-1 trial evaluating HERNEXEOS ® (zongertinib tablets) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC was presented for the first time at ESMO ...

Newswise — Triple-negative breast cancer (TNBC) is known for its aggressiveness and poor prognosis, primarily due to the lack of hormone receptor expression and HER2 amplification. Among the TNBC ...

"This study raises important questions deserving further consideration—notably how the location of the mutation in the HER2 protein and co-occurring mutations may impact the efficacy of HER2-targeting ...